A Buyout for Manager of Drug Trials
319293
One Equity Partners agreed to sell its stake in Quintiles Transnational, a big manager of clinical drug trials, to its CEO and two buyout firms.
627268
By Sharon Smyth  Merck, the German pharmaceutical company that failed to buy a rival, Schering, this year, agreed to buy the stake owned by the billionaire Ernesto Bertarelli in Serono to obtain control of the largest biotechnology company in Europe.
483706
NeoPharm Inc., a biotechnology company developing cancer treatments, said it regained ownership of two cancer compounds after Pfizer Inc.
397065
A management resignation and light earnings provide a buying opportunity.
400965
Medarex's partner advances one of its compounds into later stage clinical testing.
451993
Drug company faces first true competition to its enzyme replacement therapy for Gaucher disease.
232138
MGI Pharma Inc. MOGN.O will spend up  to $85 million for a stake in SuperGen Inc. SUPG.O and global  rights to develop and sell SuperGen's experimental drug for an  often-fatal cancer of the bone marrow, the companies said on  Wednesday.
307489
Genzyme Corp. chief executive Henri A. Termeer's conference call with Wall Street on May 8, 2003, quickly turned ugly. Analysts peppered him with questions about the Cambridge biotech company's plan to buy back shares of its biosurgery division. The price, they said, was far too low.
115767
Will the pharmacy-benefits manager risk its own health by buying diabetes-testing supplier Polymedica?
511748
Northfield announces clinical trial results that investors can learn from.
708968
Massachusetts is about to lose another corporate headquarters -- but not many jobs. In a $1.5 billion deal made public yesterday, Wakefield's PolyMedica Corp. , a mail-order company that sells drugs and supplies to diabetes patients, agreed to sell itself to Medco Health Solutions Inc., the country's biggest manager of drug benefits.
505343
BOSTON (CBS.MW) -- Merck &amp; Co. has adopted a new plan to compensate senior management in case of a corporate takeover, according to regulatory filings made Monday.
33718
Will the drugmaker's hefty R&D bill pay off?
330315
(230 sec.) How the company can offset the loss of heart drug Torcetrapib.
138104
Human Genome Sciences could see more than $180 million from a new deal with drug maker GlaxoSmithKline. Glaxo has acquired exclusive rights to an experimental drug called Albugon, which Human Genome Sciences
147168
The approval of a new drug is a long-term opportunity.
64757
International Management Group, a leading sports and celebrity management and marketing firm that has represented athletes such as Tiger Woods, Joe Montana and Derek Jeter, is being sold to funds assembled by a New York buyout specialist firm for an